Core Insights - Applied Industrial Technologies, Inc. (AIT) is experiencing growth in its technology, food & beverage, pulp & paper, and transportation markets, with the Engineered Solutions segment's revenues increasing by 13.5% year over year in Q3 of fiscal 2025 [1] Group 1: Market Performance - The Engineered Solutions segment is benefiting from strong demand in technology-related fluid power, automation, and industrial verticals, contributing to revenue growth [1] - AIT's stock has gained 31.5% over the past year, outperforming the industry growth of 9.7% [8] Group 2: Acquisitions and Growth - The company made strategic acquisitions, including IRIS Factory Automation, which is expected to enhance its automation offerings and contribute positively to sales [2] - The acquisition of Hydradyne is anticipated to boost fluid power offerings and create cross-selling opportunities, adding $260 million in sales and $30 million in EBITDA [3] Group 3: Financial Returns to Shareholders - AIT has been committed to returning value to shareholders, paying out $46.2 million in dividends in the first nine months of fiscal 2025, marking an 11.2% increase year over year [4] - The company increased its quarterly dividend rate by 24% in January 2025 and authorized a new share buyback program to repurchase up to 1.5 million shares [5] Group 4: Challenges - Despite the growth in certain segments, AIT is facing challenges in its Service Center Based Distribution segment due to reduced spending on maintenance and operations, which has negatively impacted performance [9] - The company's SG&A expenses increased by 4.1% year over year, with a rise in operating costs affecting overall profitability [10]

Key Takeaways RARE and MREO fell after delaying new data from the phase III UX143 Orbit study to year-end. The Orbit study continues as planned, with final data expected by the end of 2025. Interim safety review found UX143 acceptable, allowing studies to proceed without changes.Ultragenyx Pharmaceutical (RARE) and partner, Mereo BioPharma (MREO) , have reported an update on the progress of the mid-to-late-stage Orbit study, which is evaluating UX143 (setrusumab) for the treatment of osteogenesis imperfec ...

Core Insights - D-Wave Quantum (QBTS) shares have experienced a 0.9% decline over the past 30 days, indicating growing competitive pressures from major tech companies IBM and Alphabet (Google) as they enhance their quantum computing capabilities [1][8] Financial Performance - D-Wave reported a remarkable 509% year-over-year revenue increase in Q1 2025, driven by the sale of its Advantage2 system and real-world applications [2] - Despite this revenue surge, QBTS is trading over 20% below its all-time high reached on May 23, 2025 [2] Competitive Landscape - Investor caution is rising as IBM introduced its "Starling" roadmap, aiming for fault-tolerant quantum systems by 2029, while Google presented its "Willow" chip, which significantly reduces error rates [3][9] - D-Wave's annealing-based architecture may face limitations compared to gate-based systems from IBM and Google, which are targeting broader applications in cryptography, quantum chemistry, and advanced machine learning [3][4] Market Position and Valuation - D-Wave maintains a strong cash position of over $300 million and is seeing early adoption through initiatives like the Leap Launchpad [4] - However, analysts express concerns about D-Wave's scalability in the face of IBM and Google's aggressive market strategies, questioning whether D-Wave can remain relevant or become a niche player [4] - Currently, QBTS is trading at a forward price-to-sales ratio of 144.4X, significantly higher than its one-year median of 77.54X, indicating potential overvaluation [12]

Thursday, July 10, 2025Pre-market futures are flat this morning, again without much direction from outside influences. We’ve passed the 90-day tariff “deadline” with no ramifications; in fact, major indexes were up across the board, from a half of one percent to +1%. Currently, the Dow is -33 points, the S&P 500 is 0.0, the Nasdaq +13 points and the small-cap Russell 2000 +3.Jobless Claims Moderate on Initial Side: 227KWelcome news this Thursday morning are Weekly Jobless Claims levels, where Initial Jobles ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors by stating they were monitoring cost trends related to Medicaid "redetermination" processes and that premium rates were sufficient to cover rising costs [4]. - Contrary to these claims, the redetermination process led to a significant increase in Medicaid member utilization, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - Following a Q3 2024 earnings report on October 17, 2024, where Elevance missed EPS expectations by $1.33 (13.7%) due to elevated medical costs, the company lowered its EPS guidance for 2024 from $37.20 to $33.00 (11.3%), causing the stock price to decline by $52.61 per share, or 10.6%, to a closing price of $444.35 [7][8].

Core Points - Ford Motor is recalling over 850,000 vehicles in the US due to a fuel pump failure that may lead to engine stalling and increased crash risk [1] - The recall affects specific models from 2021 to 2023, including Bronco, Explorer, Lincoln Aviator, and F-series trucks [1] - An estimated 10% of the recalled vehicles are believed to have the defect, with at least six consumer complaints reported [3] Group 1 - The fuel pump defect can hinder fuel delivery to the engine, potentially causing stalls while driving [2] - The company has not reported any accidents or injuries related to the fuel pump failure [3] - Notifications to vehicle owners regarding the safety risk are expected to be mailed on July 14, with follow-up letters once a remedy is available [3] Group 2 - Drivers may experience symptoms such as a check engine light, reduced engine power, or poor performance prior to the fuel pump failure [4] - The defect is more likely to occur in warm weather conditions or when fuel levels are low [4]

Key Takeaways DNBBY is set to report Q2 results, with NII likely pressured by lower deposit margins. A rebound in mergers and acquisitions can support modest gains in DNBBY's investment banking revenues. Elevated personnel, benefits and restructuring costs are expected to weigh on DNBBY's Q2 expense base.DNB Bank ASA (DNBBY) is slated to announce second-quarter 2025 results tomorrow.In the last reported quarter, this Zacks Rank #3 (Hold) stock reported an increase in net interest income (NII), as well as ...

Core Insights - GE Aerospace has secured a contract with SkyWest, Inc. to provide CF34-8E engines and spares for 60 new Embraer 175 regional jets [1][9] Group 1: Engine Performance and Reliability - The CF34 engine family is recognized for its performance and reliability, with over 11,000 units delivered globally, achieving more than 209 million flight hours and 165 million flight cycles [2][9] - The engines have a dispatch reliability rate of 99.97% over a 12-month rolling period and can operate on approved sustainable aviation fuel (SAF) blends [3][9] Group 2: Business Relationships and Market Position - SkyWest has become the largest operator of GE's CF34 engines, currently operating over 1,200 GE-powered engines in its fleet [3][9] - The latest order reflects the strong, long-standing relationship between GE Aerospace and SkyWest [3] Group 3: Financial Performance and Market Outlook - GE Aerospace holds a Zacks Rank of 2 (Buy), indicating strong business performance driven by robust demand for commercial engines and technologies [4] - The company's shares have increased by 51.1% over the past year, outperforming the industry growth of 17.2% [6] - The Zacks Consensus Estimate for GE's 2025 earnings has risen by 0.2% in the past 60 days [6]

Key Takeaways Nasdaq shares have gained 45.8% in the past year compared with the industry's growth of 25%. For 2025, NDAQ expects Capital Access Platforms revenue growth in the range of 5% to 8% over the medium term. Nasdaq aims to reach 40-50% SaaS revenues as a percentage of total revenues by 2025.Shares of Nasdaq, Inc. (NDAQ) have gained 45.8% in the past year, outperforming its industry, the Finance sector and the Zacks S&P 500 composite’s growth of 25%, 18.8% and 10.1%, respectively. NDAQ has outperf ...